Nano Device for Early Cancer Detection

Topic: Treatment of Cancer
Author: Institute of Photonic Sciences (ICFO)
Published: 2014/05/18 - Updated: 2023/10/09
Publication Type: Announcement / Notification - Peer-Reviewed: Yes
Contents: Summary - Introduction - Main Item - Related Topics

Synopsis: Researchers announce development of lab-on-a-chip platform for detecting protein cancer markers in blood using advances in plasmonics, nano-fabrication, microfluids and surface chemistry. Although very compact (only a few square centimeters), the lab-on-a-chip hosts various sensing sites distributed across a network of fluidic micro-channels that enables it to conduct multiple analyses. When a drop of blood is injected into the chip, it circulates through the micro-channels and if cancer markers are present in the blood, they will stick to the nano-particles located on the micro-channels as they pass.

Introduction

Today, the majority of cancers are detected on the macroscopic level, when the tumor is already composed of millions of cancer cells and the disease is starting to advance into a more mature phase. But what if we could diagnose cancer before it took hold- while it was still only affecting a few localized cells? It would be like putting a fire out while it was still just a few sparks versus after having already caught on and spread to many areas of the house.

Main Item

An international team of researchers, led by ICFO Institute of Photonic Sciences in Castelldefels, announce the successful development of a "lab-on-a-chip" platform capable of detecting protein cancer markers in the blood using the very latest advances in plasmonics, nano-fabrication, microfluids and surface chemistry. The device is able to detect very low concentrations of protein cancer markers in blood, enabling diagnoses of the disease in its earliest stages. The detection of cancer in its very early stages is seen as key to the successful diagnosis and treatment of this disease.

Continued below image.
Picture shows the lab-on-a-chip - Photo Credit: ICFO - the Institute of Photonic Sciences
Picture shows the lab-on-a-chip - Photo Credit: ICFO - the Institute of Photonic Sciences
Continued...

This cancer-tracking nano-device shows great promise as a tool for future cancer treatments, not only because of its reliability, sensitivity and potential low cost, but also because of its easy carry-on portable properties, which is foreseen to facilitate effective diagnosis and suitable treatment procedures in remote places with difficult access to hospitals or medical clinics.

How Does it Work?

Although very compact (only a few square centimeters), the lab-on-a-chip hosts various sensing sites distributed across a network of fluidic micro-channels that enables it to conduct multiple analyses. Gold nano-particles lie on the surface of the chip and are chemically programed with an antibody receptor in such a way that they are capable of specifically attracting the protein markers circulating in blood. When a drop of blood is injected into the chip, it circulates through the micro-channels and if cancer markers are present in the blood, they will stick to the nano-particles located on the micro-channels as they pass by, setting off changes in what is known as the "plasmonic resonance". The device monitors these changes, the magnitude of which are directly related to the concentration/number of markers in the patient blood thus providing a direct assessment of the risk for the patient to develop a cancer.

Continued below image.
Picture shows gold Nano-particles in fluidic micro-channels attracting protein cancer markers. Photo Credit: ICFO - The Institute of Photonic Sciences
Picture shows gold Nano-particles in fluidic micro-channels attracting protein cancer markers. Photo Credit: ICFO - The Institute of Photonic Sciences
Continued...

ICREA Professor at ICFO Romain Quidant, coordinator of the project comments;

"The most fascinating finding is that we are capable of detecting extremely low concentrations of this protein in a matter of minutes, making this device an ultra-high sensitivity, state-of-the-art, powerful instrument that will benefit early detection and treatment monitoring of cancer."

In 2009, Prof. Quidant's research group at ICFO, in collaboration with several groups of oncologists, joined the worldwide effort devoted to the ultra-sensitive detection of protein markers located on the surface of cancer cells and in peripheral blood, which had been determined to be a clear indicator of the development of cancer.

Continued below image.
View of the lab-on-a-chip. Photo Credit: ICFO - The Institute of Photonic Sciences
View of the lab-on-a-chip. Photo Credit: ICFO - The Institute of Photonic Sciences
Continued...

In 2010, they successfully obtained funding for the project called SPEDOC (Surface Plasmon Early Detection of Circulating Heat Shock Proteins and Tumor Cells) under the 7th Framework Program (FP7) of the European Commission.

The effort was also boosted by generous philanthropic support from Cellex Foundation Barcelona. Today's announcement is an important outcome of this project.

References:

This work has been supported by Cellex Foundation Barcelona and by the SPEDOC project, funded by the Seventh Framework Program (FP7) of the European Commission.

Srdjan S Acimovic, Maria Alejandra Ortega, Vanesa Sanz, Johann Berthelot, Jose Luis Garcia-Cordero, Jan Renger, Sebastian J. Maerkl, Mark Patrick Kreuzer, and Romain Quidant, LSPR Chip for Parallel, Rapid and Sensitive Detection of Cancer Markers in Serum, Nano Letters.

Attribution/Source(s):

This peer reviewed publication was selected for publishing by the editors of Disabled World due to its significant relevance to the disability community. Originally authored by Institute of Photonic Sciences (ICFO), and published on 2014/05/18 (Edit Update: 2023/10/09), the content may have been edited for style, clarity, or brevity. For further details or clarifications, Institute of Photonic Sciences (ICFO) can be contacted at icfo.es. NOTE: Disabled World does not provide any warranties or endorsements related to this article.

Explore Related Topics

1 - - A team of scientists have taken a significant leap forward by developing a label-free SERS-Artificial intelligence method for cancer screening (SERS-AICS).

2 - - Overexpression of certain genes pointed researchers to a vulnerability that might be exploited to target cancers with aneuploidy.

3 - - A simple blood test can now detect common cancer signal across over 50 types of cancer from tumor DNA in blood.

4 - - Significant improvement in progression-free survival and response rate combined with reduced symptoms and better quality of life outcome of new treatment approach for patients with desmoid tumors.

5 - - Access to Oncology Medicines (ATOM) Coalition is a global partnership to increase access to quality-assured essential cancer medicines in low and lower middle-income countries and to help countries develop capacity for their proper use.

Complete List of Related Information

Page Information, Citing and Disclaimer

Disabled World is a comprehensive online resource that provides information and news related to disabilities, assistive technologies, and accessibility issues. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.

Cite This Page (APA): Institute of Photonic Sciences (ICFO). (2014, May 18 - Last revised: 2023, October 9). Nano Device for Early Cancer Detection. Disabled World. Retrieved October 11, 2024 from www.disabled-world.com/health/cancer/treatment/lab-on-a-chip.php

Permalink: <a href="https://www.disabled-world.com/health/cancer/treatment/lab-on-a-chip.php">Nano Device for Early Cancer Detection</a>: Researchers announce development of lab-on-a-chip platform for detecting protein cancer markers in blood using advances in plasmonics, nano-fabrication, microfluids and surface chemistry.

Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.